Boston Partners Decreases Stake in Enovis Corporation $ENOV

Boston Partners reduced its holdings in shares of Enovis Corporation (NYSE:ENOV) by 7.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 903,080 shares of the company’s stock after selling 67,900 shares during the quarter. Boston Partners’ holdings in Enovis were worth $28,310,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ENOV. Vise Technologies Inc. purchased a new position in Enovis in the 2nd quarter worth about $208,000. ProShare Advisors LLC bought a new stake in shares of Enovis in the second quarter worth approximately $400,000. Campbell & CO Investment Adviser LLC raised its holdings in shares of Enovis by 1,885.9% during the second quarter. Campbell & CO Investment Adviser LLC now owns 120,921 shares of the company’s stock valued at $3,792,000 after purchasing an additional 114,832 shares during the last quarter. Versor Investments LP purchased a new position in shares of Enovis during the second quarter valued at approximately $505,000. Finally, Simon Quick Advisors LLC bought a new position in Enovis during the second quarter valued at approximately $251,000. 98.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Needham & Company LLC cut their target price on shares of Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Canaccord Genuity Group reduced their price objective on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wells Fargo & Company raised their target price on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, UBS Group cut their price target on Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.17.

Enovis Stock Performance

Shares of ENOV opened at $31.28 on Thursday. The business has a 50-day simple moving average of $31.34 and a two-hundred day simple moving average of $31.39. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. Enovis Corporation has a 52 week low of $25.47 and a 52 week high of $49.75. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -2.19 and a beta of 1.67.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. The company had revenue of $383.81 million during the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. On average, analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Damien Mcdonald acquired 6,457 shares of Enovis stock in a transaction dated Thursday, September 11th. The stock was purchased at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the purchase, the chief executive officer directly owned 102,753 shares in the company, valued at approximately $3,182,260.41. This trade represents a 6.71% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were purchased at an average price of $29.71 per share, for a total transaction of $74,275.00. Following the completion of the transaction, the chief financial officer directly owned 116,729 shares in the company, valued at approximately $3,468,018.59. This trade represents a 2.19% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 12,157 shares of company stock worth $374,760 over the last three months. 2.70% of the stock is currently owned by company insiders.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.